Common Contracts
4 similar Underwriting Agreement contracts by Actinium Pharmaceuticals, Inc., BioNano Genomics, Inc, Liqtech International Inc, Syros Pharmaceuticals, Inc.
15,635,850 Shares1 of Common Stock 30,425,000 Pre-Funded Warrants to Purchase Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 17th, 2022 • Liqtech International Inc • Misc industrial & commercial machinery & equipment • New York
LiqTech International, Inc., a Nevada corporation (the “Company”) proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), (i) an aggregate of 15,635,850 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and (ii) 30,425,000 pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001 per share. The terms of the Pre-Funded Warrants are set forth in the form of Pre-Funded Warrant attached hereto as Exhibit B. The Company has also granted to the Underwriters an option to purchase up to 6,900,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Shares,” the Firm Shares and the
Actinium Pharmaceuticals, Inc. Common Stock, par value $0.001 per share, and Warrants to Purchase Common Stock Underwriting AgreementUnderwriting Agreement • April 18th, 2019 • Actinium Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. is acting as representative (the “Representative” or “you”), an aggregate of (i) 42,860,000 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of the Company and (ii) warrants to purchase up to 42,860,000 shares of Common Stock in the form set forth on Exhibit A (the “Warrants” and, together with the Shares, the “Securities”). Each Share is being sold together with a Warrant to purchase one share of Common Stock at an exercise price of $0.50 per whole share of Common Stock. The shares of Common Stock underlying the Warrants are herein called the “Warrant Shares”).
SYROS PHARMACEUTICALS, INC. 8,667,333 shares of common stock, par value $0.001 per share (the “Common Stock”) and Class A Warrants to Purchase up to 1,951,844 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 8th, 2019 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), (i) an aggregate of 8,667,333 shares of Common Stock of the Company (the “Shares”) and (ii) Class A Warrants, substantially in the form of Exhibit A hereto, to purchase an aggregate of 1,951,844 shares of Common Stock (the “Warrants,” such Shares and Warrants to be issued and sold by the Company being hereinafter collectively called the “Securities”). Each share was offered by the Company together with a Warrant to purchase one-quarter of one share of Common Stock at an exercise price of $8.625 per whole share; provided, that 859,957 of the Shares to be sold hereunder are being sold without such Warrants. As used herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrants. The shares of Common Stock of the Compa
BIONANO GENOMICS, INC. UNDERWRITING AGREEMENT [ ] UnitsUnderwriting Agreement • August 15th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments • New York
Bionano Genomics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Roth Capital Partners, LLC is acting as representative (the “Representative”), an aggregate of [ ] units (each a “Unit” and collectively, the “Units”), each consisting of one share of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (the “Firm Shares”) and one warrant (each a “Firm Warrant” and collectively, the “Firm Warrants”) to purchase one share of Common Stock (collectively, the “Firm Units”). The Common Stock that is issuable upon the exercise of either the Firm Warrants or the Option Warrants (as defined below) to be issued in this offering shall be referred to herein as the “Warrant Shares.” The Company also proposes to grant to the Underwriters, upon the terms and conditions set forth in Section 4 hereof,
